|Articles|March 11, 2021
- Pharmaceutical Executive-03-01-2021
- Volume 41
- Issue 3
Pharmaceutical Executive, March 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive March 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 5 years ago
The Amazon Effect: A Data-Fueled Customer Experiencealmost 5 years ago
Why ESG Performance Metrics Matteralmost 5 years ago
Pharma and Biotech’s 2020 Full-Year Viewalmost 5 years ago
Persevering for Patientsalmost 5 years ago
Biopharma’s Reputation Gets a Well-Earned Shot in the Armalmost 5 years ago
IP and Capitalalmost 5 years ago
IP and COVID-19almost 5 years ago
Pharma Steps Up for Public Health Inequitiesalmost 5 years ago
FDA Relays Recent Achievements, Maps Plans for Progressalmost 5 years ago
IP and CollaborationNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026 Preview: Roche’s Refresh
2
Pharmaceutical Executive Daily: Nine New Additions to TrumpRx
3
AstraZeneca Reaches $2 Billion License Agreement with Jacobio Pharma for Pan-KRAS Inhibitor
4
JP Morgan 2026 Preview: Eli Lilly Seeks Bounce Back
5

